|
| 37937397 | Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. | Immunotherapy | 2024 |
| 36627494 | Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. | Nature | 2023 |
| 37487665 | Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. | J Immunother Cancer | 2023 |
| 37799721 | The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. | Front Immunol | 2023 |
| 37484526 | The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition. | Ther Adv Med Oncol | 2023 |
| 37647056 | Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. | JAMA Dermatol | 2023 |
| 37541280 | National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities. | Lancet Oncol | 2023 |
| 37534686 | Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. | Melanoma Res | 2023 |
| 37193799 | Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. | Nat Med | 2023 |
| 37459873 | Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37459871 | Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials. | Lancet Oncol | 2023 |
| 36990614 | Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. | Lancet Oncol | 2023 |
| 37345026 | Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study. | Cancers (Basel) | 2023 |
| 37307533 | Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. | Am J Gastroenterol | 2023 |
| 37072748 | The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. | J Transl Med | 2023 |
| 37167764 | Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. | Eur J Cancer | 2023 |
| 37364224 | Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development. | Am Soc Clin Oncol Educ Book | 2023 |
| 36997799 | Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. | Nat Med | 2023 |
| 36477181 | Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. | Clin Cancer Res | 2023 |
| 36853577 | A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620). | Breast Cancer Res Treat | 2023 |
| 36918225 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. | J Immunother Cancer | 2023 |
| 36918220 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. | J Immunother Cancer | 2023 |
| 36780608 | Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. | J Clin Oncol | 2023 |
| 36510640 | Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. | Neuro Oncol | 2023 |
| 36894629 | Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. | Nature | 2023 |
| 34724197 | Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. | Cancer | 2022 |
| 35476655 | CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. | N Engl J Med | 2022 |
| 35705814 | Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. | Nature | 2022 |
| 35538491 | The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. | J Transl Med | 2022 |
| 35728875 | Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). | J Immunother Cancer | 2022 |
| 35435472 | A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. | Cancer Chemother Pharmacol | 2022 |
| 35762249 | Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. | Neuro Oncol | 2022 |
| 35426590 | Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). | Ann Surg Oncol | 2022 |
| 35413951 | Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. | Nat Commun | 2022 |
| 35940183 | Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2022 |
| 36206074 | Current and emerging options for patients with melanoma brain metastases. | Clin Adv Hematol Oncol | 2022 |
| 36328011 | Symptomatic melanoma CNS metastases in the TRICOTEL study - Authors' reply. | Lancet Oncol | 2022 |
| 36324592 | Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. | Front Oncol | 2022 |
| 36223314 | Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions. | Melanoma Res | 2022 |
| 36289334 | Neoadjuvant relatlimab and nivolumab in resectable melanoma. | Nature | 2022 |
| 36215947 | A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2Â and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. | Eur J Cancer | 2022 |
| 35912544 | Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. | Pigment Cell Melanoma Res | 2022 |
| 35190823 | Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. | Clin Cancer Res | 2022 |
| 35074903 | Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. | J Immunother Cancer | 2022 |
| 35089452 | Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). | Ann Surg Oncol | 2022 |
| 35030011 | Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma. | J Clin Oncol | 2022 |
| 34874127 | Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. | Cancer Med | 2022 |
| 35114123 | Nivolumab plus ipilimumab in melanoma brain metastases - Authors' reply. | Lancet Oncol | 2022 |
| 35199578 | Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma. | J Manag Care Spec Pharm | 2022 |
| 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 |